Riverview Trust Co Raises Position in Royalty Pharma plc (NASDAQ:RPRX)

Riverview Trust Co lifted its holdings in Royalty Pharma plc (NASDAQ:RPRX) by 3,953.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,216 shares of the biopharmaceutical company’s stock after purchasing an additional 1,186 shares during the quarter. Riverview Trust Co’s holdings in Royalty Pharma were worth $31,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also bought and sold shares of the business. Metis Global Partners LLC increased its position in shares of Royalty Pharma by 65.0% during the 4th quarter. Metis Global Partners LLC now owns 35,861 shares of the biopharmaceutical company’s stock valued at $915,000 after purchasing an additional 14,124 shares during the last quarter. US Bancorp DE increased its stake in Royalty Pharma by 151.3% in the 4th quarter. US Bancorp DE now owns 9,565 shares of the biopharmaceutical company’s stock worth $244,000 after buying an additional 5,759 shares in the last quarter. Proficio Capital Partners LLC purchased a new stake in shares of Royalty Pharma during the fourth quarter worth about $786,000. Bryn Mawr Capital Management LLC grew its stake in Royalty Pharma by 7.1% during the fourth quarter. Bryn Mawr Capital Management LLC now owns 9,100 shares of the biopharmaceutical company’s stock valued at $232,000 after acquiring an additional 600 shares in the last quarter. Finally, Illinois Municipal Retirement Fund grew its position in shares of Royalty Pharma by 39.3% during the fourth quarter. Illinois Municipal Retirement Fund now owns 131,615 shares of the biopharmaceutical company’s stock valued at $3,357,000 after purchasing an additional 37,136 shares in the last quarter. Hedge funds and other institutional investors own 54.35% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on RPRX shares. StockNews.com upgraded shares of Royalty Pharma from a “hold” rating to a “buy” rating in a research report on Tuesday, November 5th. TD Cowen upgraded shares of Royalty Pharma to a “strong-buy” rating in a report on Tuesday, December 24th. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $41.60.

Royalty Pharma Price Performance

Shares of NASDAQ RPRX opened at $33.64 on Friday. Royalty Pharma plc has a fifty-two week low of $24.05 and a fifty-two week high of $34.20. The business has a 50-day simple moving average of $30.06 and a two-hundred day simple moving average of $28.18. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.44 and a current ratio of 1.44. The company has a market cap of $19.39 billion, a PE ratio of 23.20, a P/E/G ratio of 2.31 and a beta of 0.49.

Royalty Pharma (NASDAQ:RPRX) last announced its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.15 EPS for the quarter, beating the consensus estimate of $0.99 by $0.16. Royalty Pharma had a net margin of 37.94% and a return on equity of 24.40%. As a group, equities analysts expect that Royalty Pharma plc will post 4.49 EPS for the current fiscal year.

Royalty Pharma Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, March 10th. Investors of record on Friday, February 21st will be issued a dividend of $0.22 per share. This represents a $0.88 annualized dividend and a yield of 2.62%. This is a positive change from Royalty Pharma’s previous quarterly dividend of $0.21. The ex-dividend date is Friday, February 21st. Royalty Pharma’s dividend payout ratio (DPR) is 60.69%.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.